EGFR and breast cancer: As epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal BC, currently cetuximab, a mAb that binds EGFR, is being tested for efficacy in TNBC (Carey et al., 2012) and it was also shown in vitro that it triggers NK-cell-mediated ADCC (Roberti et al., 2011).